{
    "id": 25136,
    "fullName": "CEP85L - ROS1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CEP85L-ROS1 results from the fusion of CEP85L and ROS1, leading to constitutive phosphorylation of Ros1 and downstream signaling molecules including Shp2, Akt, and Erk1/2, and transformation of cultured cells (PMID: 30171048). CEP85L-ROS1 has been identified in glioblastoma (PMID: 25204415, PMID: 30171048).",
            "references": [
                {
                    "id": 5799,
                    "pubMedId": 25204415,
                    "title": "The landscape of kinase fusions in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25204415"
                },
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 387119,
        "geneSymbol": "CEP85L",
        "terms": [
            "CEP85L",
            "bA57K17.2",
            "C6orf204",
            "NY-BR-15"
        ]
    },
    "variant": "CEP85L - ROS1",
    "createDate": "08/04/2016",
    "updateDate": "10/23/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 6098,
                "geneSymbol": "ROS1",
                "terms": [
                    "ROS1",
                    "c-ros-1",
                    "MCF3",
                    "ROS"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15086,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited survival of transformed cells expressing CEP85L-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 25901,
                "profileName": "CEP85L - ROS1"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15083,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited survival of transformed cells expressing CEP85L-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 25901,
                "profileName": "CEP85L - ROS1"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15084,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited survival of transformed cells expressing CEP85L-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 25901,
                "profileName": "CEP85L - ROS1"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15088,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited survival of transformed cells expressing CEP85L-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 25901,
                "profileName": "CEP85L - ROS1"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15087,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited survival of transformed cells expressing CEP85L-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 25901,
                "profileName": "CEP85L - ROS1"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15085,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited survival of transformed cells expressing CEP85L-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 25901,
                "profileName": "CEP85L - ROS1"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15082,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited survival of transformed cells expressing CEP85L-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 25901,
                "profileName": "CEP85L - ROS1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15089,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rozlytrek (entrectinib) inhibited survival of transformed cells expressing CEP85L-ROS1 in culture (PMID: 30171048).",
            "molecularProfile": {
                "id": 25901,
                "profileName": "CEP85L - ROS1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12493,
                    "pubMedId": 30171048,
                    "title": "Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30171048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25901,
            "profileName": "CEP85L - ROS1",
            "profileTreatmentApproaches": [
                {
                    "id": 19108,
                    "name": "ROS1 Inhibitor",
                    "profileName": "CEP85L - ROS1"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}